Clinical trials: Heart Failure NYHA Class II
Congestive Heart Failure
Safety and Efficacy of Furosemide 40mg + Amiloride Hydrochloride 10mg to Reduct Edema
The study consists in two treatment groups, one group will receive Diurisa® (furosemide 40 mg + amiloride chloride 10 mg) and the other one will receive furosemide 40 mg (Lasix®)
- Trial name
- NCT01210365
- Testing
- Diurisa®, Lasix ®
- Where
- 4 sites in Brazil
- Volunteers
- 27 people
- Sponsor
- Eurofarma Laboratorios S.A.
Heart Failure
REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure
This study is researching an experimental drug called REGN5381, further referred to as study drug. The study is focused on adult participants with heart failure that, in the opinion of the study doctor, have a clinical indication…
- Trial name
- NCT05353166
- Testing
- REGN5381
- Where
- Moldova
- Volunteers
- 59 people
- Sponsor
- Regeneron Pharmaceuticals
Heart Failure, Iron-deficiency
Beneficial Effects of Vitamin D Combined With Oral Iron Supplementation in Patients With Chronic Heart Failure and Iron Deficiency
The goal of this randomized, controlled, open-label, interventional study is to evaluate whether, in patients with heart failure (HF) and iron deficiency (ID), the administration of vitamin D in combination with sucrosomial iron…
- Conditions
- Heart Failure, Iron-deficiency, Heart Failure, Systolic, Heart Failure NYHA Class II
- Trial name
- VICTORID-HF (NCT05702970)
- Testing
- Sucrosomial iron, Vitamin D, Ferric Carboxymaltose 50 MG/ML
- Volunteers
- 258 people
- Sponsor
- University of Padova
Heart Failure, Heart Failure With Reduced Ejection Fraction
Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure
Heart failure (HF) is a major healthcare problem. In patients with Heart Failure with Reduced Ejection Fraction (HFrEF), aldosterone antagonists reduce mortality and hospitalization rate.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- GBDAL-HF (NCT06233695)
- Testing
- Potassium sparing diuretic
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Chronic Heart Failure
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
- Trial name
- RENEU-HF (NCT06369298)
- Testing
- JK07
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 282 people
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure With Preserved Ejection Fraction (HFpEF)
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
This study evaluated the safety and tolerability of LCZ696 treatment in Japanese heart failure patients (NYHA Class II-IV) with preserved ejection fraction after CLCZ696D2301 (PARAGON-HF).
- Trial name
- NCT03909295
- Testing
- LCZ696
- Where
- 17 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
This was a multicenter, randomized, double-blind, crossover, placebo-controlled, Phase II clinical study that evaluated the effect of serelaxin versus placebo (both in addition to SoC) on the release of hs-cTnI, in patients with…
- Trial name
- RELAX-Cardio (NCT02625922)
- Testing
- Serelaxin
- Where
- 9 sites in Germany, Switzerland and 1 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure NYHA Class IV, Heart Failure NYHA Class II
Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients
The two primary goals of it's management are preventing further disease progression(mortality,hospitalizations and deterioration of left ventricular function)and alleviating patient suffering
- Trial name
- NCT04218435
- Testing
- Sacubitril / Valsartan Oral Tablet
- Where
- Pakistan
- Volunteers
- 200 people
- Sponsor
- Clinision
Heart Failure NYHA Class I, Heart Failure NYHA Class II
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
This study tests the hypothesis that endogenous bradykinin contributes to effects of a combined angiotensin receptor blocker/neprilysin inhibitor (LCZ696 or Entresto)
- Conditions
- Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT03005184
- Testing
- Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid
- Where
- United States
- Sponsor
- Vanderbilt University Medical Center
Heart Failure NYHA Class II
Nutritional Therapy Interventions in Heart Failure
The investigators will examine the effects of 12-weeks of nutritional interventions in older participants who have a symptom of mild to moderate heart failure.
- Trial name
- NCT03424265
- Testing
- EAA mixture
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Arkansas
Heart Failure, Heart Failure NYHA Class I
Promoting Well-being and Health in Heart Failure
The focus of this study is to test the efficacy of a 12-week, phone-delivered Positive Psychology-Motivational Interviewing (PP-MI) intervention, with additional twice weekly PP and health behavior text messages for a total of 24…
- Conditions
- Heart Failure, Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT04829617
- Testing
- PP-MI Intervention, MI-alone Intervention
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Massachusetts General Hospital
Heart Failure NYHA Class II
Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure
This study is designed to compare between blood flow restricted resistance exercises and low level laser on cardiac functions in patients with chronic heart failure
- Trial name
- heart failure (NCT07045038)
- Testing
- Acupuncture LLLT:, Blood flow restricted resistance exercise:, Medical treatment
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
The goal of this observational study is to learn about SGLT2 inhibition medications in patients with symptomatic heart failure who are clinically prescribed FDA-approved SGLT2 inhibitors.
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
- Trial name
- EMAS-HF (NCT05885607)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Cognitive Intervention to Improve Memory in Heart Failure Patients
Cognitive Intervention to Improve Memory in Heart Failure patients
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class I
- Trial name
- Memoir-HF (NCT03035565)
- Testing
- Computerized Cognitive Training with Brain HQ, Computerized Crossword Puzzles
- Where
- 2 sites in United States
- Volunteers
- 276 people
- Sponsor
- Indiana University
Heart Failure, Heart Failure NYHA Class II
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
The purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF < 50%…
- Conditions
- Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- BENEFIT-HF (NCT07232030)
- Testing
- Barostim System, Usual care medical management
- Where
- 20 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- CVRx, Inc.
Heart Failure, Heart Failure NYHA Class III
HEart fAiluRe evaluaTion Questionnaire
The "four-point" questionnaire by Severo and his associates was weighted in 2011 in the Portuguese population and aims to characterize the severity of the symptoms of heart failure by providing a way to minimize the reliability…
- Conditions
- Heart Failure, Heart Failure NYHA Class III, Heart Failure NYHA Class II, Heart Failure NYHA Class I
- Trial name
- HEART (NCT03895073)
- Testing
- healthy volunteers
- Where
- Greece
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- John Parissis
Diabetes, Heart Failure
Multipolar CRT-d and Diabetes
Background: Type 2 Diabetes Mellitus (T2DM) is a multi factorial disease, affecting clinical outcomes in failing heart (HF) patients treated by Cardiac Resynchronization Therapy with a defibrillator (CRT-d).
- Conditions
- Diabetes, Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT03095196
- Testing
- Multipolar CRT-d, plus conventional drug therapy for HF., Bipolar CRT-d, plus conventional drug therapy for HF., HF drugs
- Volunteers
- 190 people
- Sponsor
- Celestino Sardu
Heart Failure New York Heart Association (NYHA) Class II, Heart Failure New York Heart Association (NYHA) Class III
Exercise Intervention in Patients With Heart Failure With Preserved and Reduced Ejection Fraction
The objective of this study is to assess by what physiological mechanisms patients with heart failure benefit from exercise. Effects of an exercise intervention will be assessed for both central (heart and lungs) and peripheral…
- Trial name
- NCT05255172
- Testing
- Supervised Exercise
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Region Skane
Chronic Heart Failure, Heart Failure NYHA Class II
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial
The purpose of this study is to investigate the effect of an early, coordinated rehabilitation intervention for patients with severe heart failure in NYHA class III and IV with a ejection fraction of <40% of normal cardiac…
- Conditions
- Chronic Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NCT01669395
- Testing
- Early homebased rehabilitation after hospital admission, Usual care
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Heart Failure NYHA Class II, Heart Failure NYHA Class III
CMR T1 Mapping for Diagnosis of Cardiac Amyloidosis
The study aims to test the diagnostic accuracy of T1 mapping for the diagnosis of cardiac amyloidosis prospectively. The hypothesis is that T1 mapping in older patients with symptomatic heart failure, increased LV wall thickness…
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure With Preserved Ejection Fraction
- Trial name
- CMR for CA (NCT04862273)
- Testing
- Native T1 CMR, Web-based ATTR probability estimator (Pfizer, New York), 99mTc-DPD scintigraphy
- Where
- Germany
- Volunteers
- 112 people
- Sponsor
- University of Leipzig